MedTrace Logo

Phase I Study of Sequential Cord Blood Transplants

NCT00299767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2016-05-11

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of sequential cord blood transplantation (2 cord blood units) for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have a matched family or volunteer unrelated donor.

Conditions

Interventions

PROCEDURE

sequential cord blood transplantation

Infused on Day 0

Sponsors & Collaborators

Principal Investigators

  • Karen Ballen, M.D. · Massachusetts General Hospital, Harvard University

  • Joseph Antin, M.D. · Dana Farber Cancer Institute, Harvard Univeristy

  • David Avigan, M.D. · Beth Israel Deaconess Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2005-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299767 on ClinicalTrials.gov